一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.7300 | -0.5100 | -43.14 | -0.6000 | | 每股净资产（元） | 3.2 | 6.02 | -46.84 | 8.27 | | 每股公积金(元) | 14.91 | 14.91 | 0 | 14.63 | | 每股未分配利润(元) | -12.73 | -9.90 | -28.59 | -7.35 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.45 | 0.68 | -33.82 | 0.04 | | 净利润(亿元) | -2.92 | -2.06 | -41.75 | -2.41 | | 净资产收益率(%) | -20.50 | -8.24 | -148.79 | -7.07 | 数据四舍五入，查看更多财务数据>> | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- ...

迈威（上海）生物科技股份有限公司2025 年第一季度报告 证券代码：688062 证券简称：迈威生物 迈威（上海）生物科技股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 单位:元 币种:人民币 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 年同期增减变 | | | --- | --- | --- | --- | | | | 上年同期 | | | | | | 动幅度(%) | | 营业收入 | 44,788,452.49 | 67,555,138.51 | -33.70 | | 归属于上市公司股东的净利润 | - ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-021 迈威（上海）生物科技股份有限公司 关于对全资子公司泰康生物增资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 增资标的名称：迈威（上海）生物科技股份有限公司（以下简称"公司" 或"迈威生物"）的全资子公司江苏泰康生物医药有限公司（以下简称"泰康 生物"）。 资金来源及增资金额：公司拟使用自有资金向泰康生物增资 40,000 万 元。 统一社会信用代码：91321291678341722J 法定代表人：刘大涛 注册资本：48,000 万元人民币 本次增资已经公司第二届董事会第十八次会议审议通过，无需提交股东 大会审议。 本次增资不构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组情形，不会改变公司合并报表范围。 一、本次增资概述 泰康生物系公司的全资子公司，按照公司集团化战略部署，公司拟使用自 有资金向泰康生物增资 40,000 万元，增资完成后，泰康生物注册资本由 48,000 万元增至 88,000 万 ...

本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 21 日 （二） 股东大会召开的地点：上海市浦东新区李冰路 576 号创想园 3 号楼 103 会议室 证券代码：688062 证券简称：迈威生物 公告编号：2025-020 迈威（上海）生物科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 138 | | --- | --- | | 普通股股东人数 | 138 | | 2、出席会议的股东所持有的表决权数量 | 199,591,712 | | 普通股股东所持有表决权数量 | 199,591,712 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 49.9478 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 49 ...

北京植德（上海）律师事务所 关于迈威（上海）生物科技股份有限公司 2024 年年度股东大会的 法律意见书 植德沪（会）字[2025]0005 号 关于迈威（上海）生物科技股份有限公司 2024 年年度股东大会的 法律意见书 植德沪（会）字[2025]0005 致：迈威（上海）生物科技股份有限公司（贵公司） 北京植德（上海）律师事务所（以下简称"本所"）接受贵公司的委托，指 派律师出席并见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理办法》（以下简称"《证券法律业务管理办法》"）、《律师 事务所证券法律业务执业规则（试行）》（以下简称"《证券法律业务执业规则》"） 等相关法律、行政法规、规章、规范性文件及《迈威（上海）生物科技股份有限 公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程 序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜 ...

迈威（上海）生物科技股份有限公司 2024 年年度股东大会会议资料 2025 年 4 月 | 2024 年年度股东大会会议须知 2 | | --- | | 2024 年年度股东大会会议议程 4 | | 2024 年年度股东大会会议议案 6 | | 议案一、关于公司《2024 年年度报告》及摘要的议案 6 | | 议案二、关于公司《2025 年度财务预算报告》的议案 7 | | 附件一：2025 年度财务预算报告 8 | | 议案三、关于公司《2024 年度财务决算报告》的议案 9 | | 附件二：2024 年度财务决算报告 10 | | 议案四、关于公司 2024 年度利润分配方案的议案 13 | | 议案五、关于续聘公司 2025 年度审计机构的议案 14 | | 附件三：拟聘会计师事务所的基本情况 15 | | 议案六、关于公司《2024 年度董事会工作报告》的议案 17 | | 附件四：2024 年度董事会工作报告 18 | | 议案七、关于公司《2024 年度监事会工作报告》的议案 25 | | 附件五：2024 年度监事会工作报告 26 | | 议案八、关于公司 2025 年度董事、监事薪酬方案的议 ...

Core Viewpoint - The company, Maiwei Biotech, is facing severe financial challenges, including significant losses and cash flow issues, prompting multiple rounds of financing to sustain operations [1][2][4][5]. Financial Performance - Maiwei Biotech reported a revenue of 200 million yuan in 2024, a year-on-year increase of 56.28%, but still incurred a net loss of 1.044 billion yuan, with losses slightly narrowing by 0.9% compared to the previous year [1]. - Cumulative losses over three years reached 3.052 billion yuan, with daily cash burn averaging nearly 2.8 million yuan [2]. - The company's operating cash flow has been negative for three consecutive years, totaling a cash outflow of 2.458 billion yuan [4]. Financing Activities - The company has initiated a series of financing efforts, including a recent plan to issue up to 500 million yuan in targeted debt financing tools [1][5]. - The credit and financing limits have been increased from 2.3 billion yuan to 6.2 billion yuan over the past year [5]. Research and Development - Maiwei Biotech has invested heavily in R&D, with cumulative expenses reaching 2.378 billion yuan from 2022 to 2024, which is 6.7 times the total revenue during the same period [2]. - The company has three commercialized products but has struggled to generate significant sales, with total drug sales in 2023 amounting to only 42.09 million yuan, far below expectations [3]. Market Position and Challenges - The company aimed to replicate the success of peers like Heng Rui Medicine but has faced challenges in product sales and market penetration [3]. - The asset-liability ratio has surged from 24% at the time of listing to 63.61%, indicating increasing financial risk [4]. Management and Operational Issues - The company has experienced significant turnover in its management team, with key personnel leaving, which may impact its operational capabilities [8]. - The R&D team has been reduced by 30% from 568 members in 2022 to 403 in 2024, raising concerns about the company's innovation potential [8]. Future Outlook - Despite attempts to secure funding through various channels, the company must address low R&D efficiency and a scattered strategic focus to avoid a cycle of financing and losses [9].

Core Viewpoint - Maiwei Biotech (688062) reported a net loss exceeding 1 billion yuan for 2024, with an increasing debt-to-asset ratio surpassing 60%, prompting the company to seek financing to improve its financial position [1][4]. Financial Performance - In 2024, Maiwei Biotech achieved an operating revenue of approximately 200 million yuan, representing a year-on-year growth of 56.28% [1][2]. - The net profit attributable to shareholders was -1.044 billion yuan, slightly improved from -1.053 billion yuan in the previous year [2][3]. - Total assets decreased by 4.03% to approximately 4.276 billion yuan compared to 2023 [2]. Product and R&D Pipeline - Despite having three products on the market, the company has not yet achieved profitability and has accumulated losses [3]. - Maiwei Biotech has 16 products in various stages of development, including 12 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases [3]. - The company emphasizes the combination use of ADC, IO, and TCE as a significant development direction and plans to explore combination therapies with external products [3]. Financing and Debt Management - The company's reliance on external financing has led to a rising debt-to-asset ratio, which increased from 24% in 2022 to 63.61% in 2024 [4]. - To optimize its debt structure and reduce financial costs, Maiwei Biotech plans to issue targeted debt financing tools not exceeding 500 million yuan [4]. - The company is also planning to list in Hong Kong to meet its funding needs and enhance its international presence [4].

Group 1 - Galaxy Fund recently conducted research on 10 listed companies, including Baile Tianheng, Maiwei Bio, and Zhonghang Heavy Machinery [1][2][3] - Baile Tianheng achieved revenue of 582.27 million yuan in 2024, a year-on-year increase of 936.31%, and net profit of 370.75 million yuan, turning a profit [1] - Maiwei Bio made progress in ADC and TCE platforms, collaborating with Insilico Medicine to enhance ADC development efficiency using AI technology [2] - Zhonghang Heavy Machinery's 2025 revenue target is 11.5 billion yuan, with a profit target of 1.3 billion yuan, and expects stable demand in Q1 2024 [3] Group 2 - Olin Bio is advancing its recombinant pneumococcal vaccine phase III clinical trial, with over 5,600 cases enrolled [3] - Haizheng Pharmaceutical anticipates growth in raw materials, formulations, and e-commerce by 2025, with a focus on reducing costs and enhancing product competitiveness [4] - Semir Apparel reported total revenue of 14.63 billion yuan in 2024, a 7.06% increase, with children's apparel accounting for 70.21% of revenue [5] Group 3 - Huayang Group's automotive electronics business is optimizing customer structure, with an increase in major clients and new projects [6] - Huafeng Chemical's gross margin declined due to lower margins in basic chemical products, but it is optimistic about future demand for spandex [7] - Ruifeng New Materials is addressing increased accounts receivable due to new and existing customer sales, while planning to enhance its global market share through innovation [8] Group 4 - Weixing Co. achieved significant growth in its button and zipper business, with zipper revenue increasing by 16% and button revenue by 22% in 2024 [9] - The company aims for a revenue target of 5 billion yuan in 2025, focusing on becoming a global and innovative fashion accessory leader [9] - The company is also expanding its production capacity and enhancing its competitive advantages through product diversity and innovation [9]

Core Viewpoint - The company, Maiwei Biotech, is facing significant financial challenges, having accumulated losses exceeding 30 billion yuan since its IPO in 2022, and is now seeking to raise funds through various financing methods to maintain operations and manage its debt levels [1][2][3]. Financing and Debt Management - Maiwei Biotech plans to apply for the issuance of targeted debt financing tools not exceeding 5 billion yuan to optimize its debt structure and reduce financial costs [1]. - The company has increased its credit and financing limits from an initial 2.3 billion yuan to 6.2 billion yuan in 2024 [1][3]. - As of the end of 2024, the company's debt-to-asset ratio has surged to 63.61%, with net cash flow from operating activities reported at -9.56 billion yuan [3]. Financial Performance - The company reported net losses of 9.55 billion yuan, 10.53 billion yuan, and 10.44 billion yuan for the years 2022 to 2024, totaling over 30 billion yuan in losses [2][3]. - Cumulative R&D expenses from 2022 to 2024 approached 24 billion yuan, indicating a heavy investment in new drug development [2]. Product Pipeline and R&D Challenges - Maiwei Biotech has 16 core products in various stages of development, with only 3 approved for market release [1][2]. - The company has faced personnel turnover, including the departure of key figures such as Zhang Jinchao, who was instrumental in the development of antibody drugs [4][5]. Corporate Structure and Strategy - The company has expanded its operations through multiple acquisitions, spending 366 million yuan to acquire five companies since 2018, which has led to a complex corporate structure with 18 subsidiaries [6][7]. - Despite the extensive network of subsidiaries, only three are currently profitable, raising concerns about the sustainability of the business model [7]. Industry Context - The biotech industry is characterized by high R&D costs and long development timelines, with an average cost exceeding 1 billion USD and a development period of over 10 years for new drugs [3]. - Analysts suggest that the company's early investment in production capabilities may be premature given its current stage of development, leading to questions about its strategic direction [8].